Danske Bank A/S
10.2.2021 09:08:23 CET | Globenewswire | Press release
10 February 2021
Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.
Akelius Residential Property Financing B.V.
Post-stabilisation Period Announcement
Further to the pre-stabilisation period announcement dated 9 February 2021, Danske Bank A/S (contact: Syndicate – Morten Grove; telephone: + 45 45 14 70 33) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
Securities
| Issuer: | Akelius Residential Property Financing B.V. |
| Guarantor(s) (if any): | Akelius Residential Property AB (publ) |
| Aggregate nominal amount: | EUR 600,000,000 |
| Description: | EUR 600,000,000 0.750 per cent. Unsecured Fixed Rate Notes due 22 February 2030, ISIN: XS2301127119 |
| Offer price: | 98.983 per cet. |
Stabilisation Manager(s)
| Name(s): | BNP Paribas, Danske Bank and Swedbank |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre24.10.2026 11:00:00 CEST | Press release
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
